Skip to main content
. 2024 Sep 11;11:1432628. doi: 10.3389/fmed.2024.1432628

Figure 3.

Figure 3

Pathologies discussed in MTB, are common and rare. Leiomyosarcoma (LMS); colon adenocarcinoma (CRC); breast carcinoma (BC); lung adenocarcinoma (L-ADC); pancreatic adenocarcinoma (P-ADC); cholangiocarcinoma (CCA); salivary adenocarcinoma (S-ADC); melanoma (SSM); ovarian carcinoma (OC); pheochromocytoma (PCC); poorly differentiated enteric-type carcinoma (pdEC); splenic angiosarcoma (PSA); angiosarcoma/hepatic carcinoma (PHA); gastric carcinoma (GC); endometrial carcinoma (EC); anal squamous cell carcinoma (SCCA); dedifferentiated liposarcoma (DDLPS); testicular carcinoma (TC); biliary tract carcinoma (BTC); hepatic carcinoma (HC); gliosarcoma (GS); desmoplastic small-round-cell carcinoma (DSRCT); squamous cell carcinoma in the cervical lymph nodes (SCC-CL); anaplastic astrocytoma (ANA); yolk sac tumor (YST); bone metastasis of carcinoma with sarcomatoid features (sBMC); myxoid liposarcoma (MLPS); atypical meningioma (AM); poorly differentiated mucinous carcinoma of gastrointestinal origin (MGC); clivus chordoma (CC); sarcoid myxofibrosarcoma (sMFS); pleomorphic rhabdomyosarcoma (PRMS); granulosa cell cancer (GCT); and atypical teratoid rhabdoid tumor (ATRT).